LupusTrials.org First posted October, 2021, Updated January, 2022; Recruiting CATEGORIES: Lupus The purpose of this Phase 2a PREVAIL-2 trial is to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) patients with active disease after amelioration induced by corticosteroid treatment. To Learn More Contact Clinical Operations at 857-675-1664 or …
Archives: Trials
A novel Phase 2 double-blind, randomized, controlled clinical trial to evaluate the efficacy of centrally acting, non-toxic ACE inhibition in cognitive impairment associated with SLE
First posted July, 2020, Updated November, 2021; Recruiting CATEGORIES: CNS Lupus This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function. The investigators will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory …
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
First posted September, 2020, Updated September, 2021; Recruiting CATEGORIES: Lupus Nephritis The objectives of this Phase 2, Double-Blind, Randomized, Placebo-Controlled Study is to evaluate the efficacy and safety of ravulizumab in adult participants With proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN) To Learn More Contact Contact: Alexion Pharmaceuticals, Inc.at 855-752-2356 or clinicaltrials@alexion.com ClinicalTrials.gov identifier: …
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
First filed December 23, 2020, Updated July 2022; Recruiting CATEGORIES: General SLE The purpose of this Phase 2 study is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active SLE. This study is being offered at 20 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed …
A Phase 2 of VIB7734 for the Treatment of Moderate to Severely Active SLE (RECAST SLE)
First filed June, 2021, Updated June, 2021; Recruiting CATEGORIES: General SLE The purpose of this Phase 2 randomized, double-blind, placebo-controlled study is to study the safety and efficacy of VIB7734 for the treatment of moderate to severely active Systemic Lupus Erythematosus in approximately 195 participants. This study is being offered at 7 LuCIN sites – …
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
CATEGORIES: General SLE This randomized, multi-site, adaptive, open-label clinical trial will compare the immune response to different COVID-19 vaccine booster doses in participants with autoimmune disease requiring immunosuppressive medications. To Learn More Contact Judith A. James, MD, PhD, Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation Meggan C. Mackay, MD, MS, Center of Autoimmune …
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)
The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab 300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features). To Learn More Contact Novartis Pharmaceuticals at 1-888-669-6682 or …
A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care (TOPAZ-1
First filed May 2021; Recruiting The primary objective of this Phase 3 randomized, double-blind, placebo-controlled study is to test the efficacy of BIIB059 compared with placebo in participants with active systemic lupus erythematosus (SLE), who are receiving background lupus standard of care (SOC) therapy in reducing disease activity. This study is being offered at 20 LuCIN …
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis (EQUALISE)
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis. To Learn More Contact: Study Contact: Catherine Kim, 858 412 5302 or clinicaltrials@equilliumbio.com ClinicalTrials.gov Identifer: NCT04128579 …
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)
CATEGORIES: General SLE The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. To Learn More Contact: Contact: UCB Cares +1844599 ext 2273 UCBCares@ucb.com ClinicalTrials.gov Identifer: NCT04294667 …